Metastatic Hepatocellular Carcinoma clinical trials

Explore recruiting metastatic hepatocellular carcinoma clinical trials.

Recruiting metastatic hepatocellular carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Hepatocellular Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2/3, Randomized Study to Evaluate the Optimized dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) who have not previously received systemic treatment

Italy, France, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)

Germany, Portugal, Italy, Ireland, Denmark, Spain +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Belgium, France, Italy, Germany, Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab for locally advanced or Metastatic Hepatocellular Carcinoma patients who have progressed after an approved immune checkpoint inhibitor containing regimen in First-Line HCC

France, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in combination with Nivolumab and Lenvatinib compared to Double Placebo and Lenvatinib in Participants with Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) after Failure of First-Line Treatment that Included an Anti-PD-(L)1 Compound (GDFATHER-HCC-01)

Germany, France, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Metastatic Hepatocellular Carcinoma trials by city

Metastatic Hepatocellular Carcinoma clinical trials

Recruiting metastatic hepatocellular carcinoma studies right now

Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS

Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients

Needle-based Percutaneous Ablation of Liver Tumors.

FGF19 Overexpression Combination Unified Study in HCC-19

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

A Study of MGC026 in Participants With Advanced Solid Tumors

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Also recruiting in Europe

A Phase 2/3, Randomized Study to Evaluate the Optimized dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) who have not previously received systemic treatment

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Metastatic Hepatocellular Carcinoma trials by city

Other conditions